Your browser doesn't support javascript.
loading
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu, Heikki; Eriksson, Mikael; Sundby Hall, Kirsten; Reichardt, Annette; Hermes, Barbara; Schütte, Jochen; Cameron, Silke; Hohenberger, Peter; Jost, Philipp J; Al-Batran, Salah-Eddin; Lindner, Lars H; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Kallio, Raija; Jaakkola, Panu; Junnila, Jouni; Alvegård, Thor; Reichardt, Peter.
Afiliación
  • Joensuu H; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Eriksson M; Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden.
  • Sundby Hall K; Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Reichardt A; Helios Klinikum Berlin-Buch, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany.
  • Hermes B; Universitätsklinikum Tübingen, Tübingen, Germany.
  • Schütte J; Schwerpunktpraxis Oncology/Hematology, Düsseldorf, Germany.
  • Cameron S; Department of Gastroenterology, University of Göttingen, Göttingen, Germany.
  • Hohenberger P; Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, Germany.
  • Jost PJ; Medical Department III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Al-Batran SE; Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt, Germany.
  • Lindner LH; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Bauer S; Sarcoma Center, West German Cancer Center, Essen, Germany.
  • Wardelmann E; Gerhard-Domagk-Institute of Pathology, University of Münster, Münster, Germany.
  • Nilsson B; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Kallio R; Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
  • Jaakkola P; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Junnila J; 4Pharma Ltd, Turku, Finland.
  • Alvegård T; Department of Cancer Epidemiology, Lund University, Lund, Sweden.
  • Reichardt P; Helios Klinikum Berlin-Buch, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany.
JAMA Oncol ; 6(8): 1241-1246, 2020 08 01.
Article en En | MEDLINE | ID: mdl-32469385
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores del Estroma Gastrointestinal / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Neoplasias Gastrointestinales / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Oncol Año: 2020 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores del Estroma Gastrointestinal / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Neoplasias Gastrointestinales / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Oncol Año: 2020 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos